FDA Approves Camzyos as First Treatment for Children with Rare Heart Condition
BMY sits 48% above its 52-week low of $42.52.
Summary
The FDA approved Camzyos (mavacamten) for children with symptomatic obstructive hypertrophic cardiomyopathy, making it the first drug for this pediatric indication. The approval expands the drug's label beyond adults, opening a new patient population. The boxed warning for heart failure risk and REMS restriction add safety considerations but do not negate the commercial opportunity. This follows a strong Q2 and recent pipeline momentum, though the company also paused its Zola-Cel program earlier this month.
At the time of this announcement, BMY was trading at $62.84 on NYSE in the Life Sciences sector, with a market capitalization of approximately $128.3B. The 52-week trading range was $42.52 to $68.64. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.